Zapping prostate cancer with guided radiation and supercharged immunity
NCT ID NCT04946370
Summary
This study is for men with advanced prostate cancer that has spread and stopped responding to standard hormone-blocking treatments. Researchers are testing if adding a new, targeted radiation drug (225Ac-J591) to a standard immunotherapy (pembrolizumab) and hormone therapy works better than the immunotherapy and hormone therapy alone. The radiation drug is designed to seek out and deliver a powerful dose directly to prostate cancer cells throughout the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Cancer Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
New York Presbyterian/Brooklyn Methodist Hospital
Brooklyn, New York, 11215, United States
-
New York Presbyterian/Weill Cornell Medical Center
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.